Skip to main content
Top
Published in: Journal of Neuro-Oncology 2/2009

01-09-2009 | Laboratory Investigations - Human/Animal Tissue

No association of (−131C→G) variant of CHI3L1 gene with risk of glioblastoma and prognosis

Authors: Blandine Boisselier, Yannick Marie, Soufiane El Hallani, Gentian Kaloshi, Anton Iershov, Vadym Kavsan, Dimitri Psimaras, Joëlle Thillet, Khe Hoang-Xuan, Jean-Yves Delattre, Marc Sanson

Published in: Journal of Neuro-Oncology | Issue 2/2009

Login to get access

Abstract

Expression of CHI3L1 (YKL-40) has been correlated with prognosis of glioblastoma. The variant allele (−131C→G) of CHI3L1 promoter results in a lower transcription of CHI3L1. Therefore, we tested the hypothesis that the G variant could protect against the risk of gliomas or have a favorable prognostic impact. DNA from 296 glioblastoma patients and 190 controls were genotyped on the −131 allele. Tumor RNA was obtained from 108 patients for CHI3L1 transcript quantification. Neither genotype nor allele distribution differed between patients and controls. There was no significant difference in survival between the CC, CG, and GG patients despite the few GG patients tended to have a longer survival. There was no correlation between genotype and CHI3L1 expression in tumor samples. Taken together our data suggest that the variant allele (−131C→G) of CHI3L1 promoter has no significant impact on survival and is not a prognostic factor for glioblastoma.
Literature
1.
go back to reference Johansen JS (2006) Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer. Dan Med Bull 53:172–209PubMed Johansen JS (2006) Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer. Dan Med Bull 53:172–209PubMed
2.
go back to reference Tanwar MK, Gilbert MR, Holland EC (2002) Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma. Cancer Res 62:4364–4368PubMed Tanwar MK, Gilbert MR, Holland EC (2002) Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma. Cancer Res 62:4364–4368PubMed
6.
go back to reference Malinda KM, Ponce L, Kleinman HK, Shackelton LM, Millis AJ (1999) Gp38k, a protein synthesized by vascular smooth muscle cells, stimulates directional migration of human umbilical vein endothelial cells. Exp Cell Res 250:168–173. doi:10.1006/excr.1999.4511 PubMedCrossRef Malinda KM, Ponce L, Kleinman HK, Shackelton LM, Millis AJ (1999) Gp38k, a protein synthesized by vascular smooth muscle cells, stimulates directional migration of human umbilical vein endothelial cells. Exp Cell Res 250:168–173. doi:10.​1006/​excr.​1999.​4511 PubMedCrossRef
8.
go back to reference Hormigo A, Gu B, Karimi S, Riedel E, Panageas KS, Edgar MA, Tanwar MK, Rao JS, Fleisher M, DeAngelis LM, Holland EC (2006) YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas. Clin Cancer Res 12:5698–5704. doi:10.1158/1078-0432.CCR-06-0181 PubMedCrossRef Hormigo A, Gu B, Karimi S, Riedel E, Panageas KS, Edgar MA, Tanwar MK, Rao JS, Fleisher M, DeAngelis LM, Holland EC (2006) YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas. Clin Cancer Res 12:5698–5704. doi:10.​1158/​1078-0432.​CCR-06-0181 PubMedCrossRef
9.
go back to reference Zhao X, Tang R, Gao B, Shi Y, Zhou J, Guo S, Zhang J, Wang Y, Tang W, Meng J, Li S, Wang H, Ma G, Lin C, Xiao Y, Feng G, Lin Z, Zhu S, Xing Y, Sang H, St Clair D, He L (2007) Functional variants in the promoter region of Chitinase 3-like 1 (CHI3L1) and susceptibility to schizophrenia. Am J Hum Genet 80:12–18. doi:10.1086/510438 PubMedCrossRef Zhao X, Tang R, Gao B, Shi Y, Zhou J, Guo S, Zhang J, Wang Y, Tang W, Meng J, Li S, Wang H, Ma G, Lin C, Xiao Y, Feng G, Lin Z, Zhu S, Xing Y, Sang H, St Clair D, He L (2007) Functional variants in the promoter region of Chitinase 3-like 1 (CHI3L1) and susceptibility to schizophrenia. Am J Hum Genet 80:12–18. doi:10.​1086/​510438 PubMedCrossRef
10.
go back to reference Ober C, Tan Z, Sun Y, Possick JD, Pan L, Nicolae R, Radford S, Parry RR, Heinzmann A, Deichmann KA, Lester LA, Gern JE, Lemanske RF Jr, Nicolae DL, Elias JA, Chupp GL (2008) Effect of variation in CHI3L1 on serum YKL-40 level, risk of asthma, and lung function. N Engl J Med 358:1682–1691. doi:10.1056/NEJMoa0708801 PubMedCrossRef Ober C, Tan Z, Sun Y, Possick JD, Pan L, Nicolae R, Radford S, Parry RR, Heinzmann A, Deichmann KA, Lester LA, Gern JE, Lemanske RF Jr, Nicolae DL, Elias JA, Chupp GL (2008) Effect of variation in CHI3L1 on serum YKL-40 level, risk of asthma, and lung function. N Engl J Med 358:1682–1691. doi:10.​1056/​NEJMoa0708801 PubMedCrossRef
11.
go back to reference Stupp R, van den Bent MW, Weller MJ, Fisher M, Taphoorn B, Belanger MJ, Brandes K, Marosi AA, Bogdahn C, Curschmann U, Janzer J, Ludwin RC, Gorlia SK, Allgeier T, Lacombe A, Cairncross D, Eisenhauer JG, Mirimanoff E, R. O. European Organisation for Research, Treatment of Cancer Brain Tumor, Radiotherapy Groups, National Cancer Institute of Canada Clinical Trials Group (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996. doi:10.1056/NEJMoa043330 PubMedCrossRef Stupp R, van den Bent MW, Weller MJ, Fisher M, Taphoorn B, Belanger MJ, Brandes K, Marosi AA, Bogdahn C, Curschmann U, Janzer J, Ludwin RC, Gorlia SK, Allgeier T, Lacombe A, Cairncross D, Eisenhauer JG, Mirimanoff E, R. O. European Organisation for Research, Treatment of Cancer Brain Tumor, Radiotherapy Groups, National Cancer Institute of Canada Clinical Trials Group (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996. doi:10.​1056/​NEJMoa043330 PubMedCrossRef
12.
go back to reference Schwartzbaum J, Jonsson F, Ahlbom A, Preston-Martin S, Lönn S, Söderberg KC, Feychting M (2003) Cohort studies of association between self-reported allergic conditions, immune-related diagnoses and glioma and meningioma risk. Int J Cancer 106:423–428. doi:10.1002/ijc.11230 PubMedCrossRef Schwartzbaum J, Jonsson F, Ahlbom A, Preston-Martin S, Lönn S, Söderberg KC, Feychting M (2003) Cohort studies of association between self-reported allergic conditions, immune-related diagnoses and glioma and meningioma risk. Int J Cancer 106:423–428. doi:10.​1002/​ijc.​11230 PubMedCrossRef
13.
14.
go back to reference Wrensch M, Wiencke JK, Wiemels J, Miike R, Patoka J, Moghadassi M, McMillan A, Kelsey KT, Aldape K, Lamborn KR, Parsa AT, Sison JD, Prados MD (2006) Serum IgE, tumor epidermal growth factor receptor expression, and inherited polymorphisms associated with glioma survival. Cancer Res 66:4531–4541. doi:10.1158/0008-5472.CAN-05-4032 PubMedCrossRef Wrensch M, Wiencke JK, Wiemels J, Miike R, Patoka J, Moghadassi M, McMillan A, Kelsey KT, Aldape K, Lamborn KR, Parsa AT, Sison JD, Prados MD (2006) Serum IgE, tumor epidermal growth factor receptor expression, and inherited polymorphisms associated with glioma survival. Cancer Res 66:4531–4541. doi:10.​1158/​0008-5472.​CAN-05-4032 PubMedCrossRef
15.
Metadata
Title
No association of (−131C→G) variant of CHI3L1 gene with risk of glioblastoma and prognosis
Authors
Blandine Boisselier
Yannick Marie
Soufiane El Hallani
Gentian Kaloshi
Anton Iershov
Vadym Kavsan
Dimitri Psimaras
Joëlle Thillet
Khe Hoang-Xuan
Jean-Yves Delattre
Marc Sanson
Publication date
01-09-2009
Publisher
Springer US
Published in
Journal of Neuro-Oncology / Issue 2/2009
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI
https://doi.org/10.1007/s11060-009-9817-4

Other articles of this Issue 2/2009

Journal of Neuro-Oncology 2/2009 Go to the issue